JOURNAL OF INTERNATIONAL CRISIS AND RISK COMMUNICATION RESEARCH
ISSN: 2576-0017
2024, VOL 7, NO S12

# Nanotechnology in Drug Delivery

**Safaa Mohammed Mobark Ahmed[1], Maisam Ahmed Alrefaei[2], Humod Obaid Ganfd Alotiabi[3], Ghazi Yahia Ali Homadi[4], Ahmed Abdulrahman Ibrahim Alarifi[5], Bassam Rubayyi Almutairi[6], Mohammed Salem Mubarak Al Dosari[7], Ahlam Ayidh Mohd Alosaimi[8], Khalid Ahmad Salem Basalem[9], Mansour Nahi Saleh Alghamdi[10]**

*1 Pharmacist, King abdulaziz hospital, Saudi Arabia.*
*2 Pharmacy Technician, Health Sector in Yanbu, Saudi Arabia, Saudi Arabia.*
*3 Assisant pharmacist, Aldwadmi Hospital, Saudi Arabia.*
*4 Pharmacy Technician, Samtah General Hospital, Saudi Arabia.*
*5 Pharmacists Technicians, ALSHARA PHCC, Saudi Arabia.*
*6 PharmD, Alafaliq Hospital for Long Term Care, Saudi Arabia.*
*7 Pharmacy technician, Durma General Hospital, Saudi Arabia.*
*8 PHARMACIST, AlQuwayiyah General Hospital, Saudi Arabia.*
*9 Pharmacist, King Abdul aziz hospital, Saudi Arabia.*
*10 Pharmacy Technician, Prince Meshari Bin Saud Hospital, Saudi Arabia.*

**Background:** Nanotechnology has revolutionized the pharmaceutical industry by offering innovative solutions to long-standing challenges in drug delivery. This field utilizes nanoparticles—materials ranging in size from 1 to 100 nanometers—to improve drug solubility, bioavailability, targeted delivery, and controlled release. By enhancing therapeutic efficacy while minimizing side effects, nanotechnology is paving the way for a new era in medicine.

**Aim:** By increasing drug solubility, stability, and bioavailability, nanotechnology in drug delivery seeks to maximize therapeutic efficacy by facilitating targeted distribution to sick tissues while reducing adverse effects. It aims to offer controlled or prolonged medication release for reliable therapeutic effects while overcoming biological barriers like the blood-brain barrier. Nanotechnology seeks to enhance precision medicine and improve patient outcomes by lowering systemic toxicity and combining diagnostics and treatment (theragnostic).

**Conclusion:** Nanotechnology has undeniably transformed drug delivery, addressing challenges in drug solubility, stability, and targeting. Although significant hurdles remain, continued research and innovation in this field are expected to yield breakthroughs that will further improve patient care and outcomes. As technology matures, nanomedicine could become a cornerstone of personalized and precision medicine.

**Keywords:** Nanotechnology, drug delivery, nanoparticles, targeted therapy, bioavailability.

## Introduction

### Targeted Drug Delivery

By utilizing their distinct size, surface characteristics, and functionalization potential, nanoparticles are particularly made to increase the accuracy and effectiveness of medication delivery. Because of their tiny size, they can pass past biological barriers and gather tissues, frequently using mechanisms like the increased permeability and retention (EPR) effect, which is very helpful when targeting tumors. Their capacity to bind specifically to disease-specific cell receptors is further improved by functionalization with ligands like aptamers, peptides, or antibodies.[1]

For instance, hydrophilic or hydrophobic medications are encapsulated in liposomes, which are spherical vesicles with a phospholipid bilayer that prevents disintegration and permits prolonged release at the tumor site. Because they increase drug accumulation in tumors and decrease cardiotoxicity, FDA-approved liposomal formulations such as Doxil® (doxorubicin) have shown better results in the treatment of cancer.[2]

Likewise, biodegradable polymeric nanoparticles, such as poly (lactic-co-glycolic acid) (PLGA), can be designed to release drugs in a regulated and sustained manner. These nanoparticles offer adaptability in the treatment of various diseases because they can encapsulate biologics as well as small compounds. They lessen systemic exposure to cytotoxic chemicals during cancer treatment, minimizing common adverse effects such bone marrow suppression and nausea.[3]

Nanoparticles' wide range of therapeutic applications is demonstrated by their investigation into targeted delivery in cardiovascular, neurological, and infectious diseases in addition to cancer. medication delivery methods based on nanoparticles greatly improve therapeutic efficacy and safety by decreasing off-target effects and raising medication concentration at the intended location.[4]

**Improved Drug Solubility and Stability**

Poor water solubility makes it difficult for many medications to reach appropriate therapeutic levels, especially those categorized as class II (low solubility, high permeability) and class IV (low solubility, low permeability) by the Biopharmaceutical Classification System (BCS). Solid lipid nanoparticles (SLNs) and micelles are two examples of nanocarriers that provide efficient answers to this issue.[5]

Micelles, which are made of amphiphilic molecules, encapsulate poorly soluble medications in a hydrophobic core, increasing their stability and solubility in aqueous solutions. This method improves the absorption and bioavailability of hydrophobic medications by facilitating their systemic distribution. Another interesting platform is solid lipid nanoparticles, which are composed of biocompatible lipids that solidify at body temperature or room temperature. In addition to offering regulated release and protection against degradation, SLNs offer a stable matrix for drug encapsulation, which increases bioavailability. These nanocarriers transform therapy for diseases requiring specific therapeutic action by increasing the solubility of hydrophobic medications and facilitating their safe and efficient distribution to target tissues.[6]

**Controlled Release Systems**

Nanotechnology facilitates the development of advanced drug delivery systems that enable controlled and sustained therapeutic release, ensuring consistent drug levels in the bloodstream over extended periods. This approach minimizes peaks and troughs in drug concentration, enhancing efficacy while reducing side effects. Nanospheres, for example, are spherical nanoparticles made from biodegradable polymers that encapsulate drugs. These can be engineered to release their payload gradually, achieving sustained drug release. Such systems are particularly beneficial for chronic conditions, as they reduce the need for frequent dosing, improving patient adherence and convenience. Controlled release nanocarriers are being explored for various applications, including pain management, hormonal therapies, and chemotherapy, offering significant advantages over conventional drug formulations.[7]

**Crossing Biological Barriers**

Nanoparticles have demonstrated the capability to cross biological barriers, such as the blood-brain barrier (BBB), a critical hurdle in treating neurological disorders. The BBB, composed of tightly packed endothelial cells, restricts the entry of most therapeutic agents into the central

nervous system (CNS), limiting the efficacy of treatments for conditions like Alzheimer's disease, Parkinson's disease, and brain tumors.[8]

Functionalized nanoparticles, engineered with specific surface modifications, can traverse the BBB through mechanisms such as receptor-mediated transcytosis or adsorption-mediated uptake. For example, nanoparticles conjugated with ligands targeting transferrin or low-density lipoprotein (LDL) receptors can effectively deliver drugs across the BBB.[9]

Liposomes, dendrimers, and polymeric nanoparticles are among the nanocarriers being explored for CNS drug delivery. These systems can encapsulate both small molecules and biologics, protect them from degradation, and release them in a controlled manner at the target site. By overcoming the BBB, nanoparticle-based systems hold promise for revolutionizing the treatment of neurological diseases, potentially improving therapeutic outcomes and reducing systemic side effects.[10]

**Advances in Nanotechnology Platforms**

**Liposomes**

Both hydrophilic (water-soluble) and hydrophobic (fat-soluble) medications can be encapsulated in liposomes, which are spherical vesicles made of one or more phospholipid bilayers. Their unique structure enhances the stability, solubility, and bioavailability of a variety of medicinal medicines, making them an ideal carrier. Additionally, the lipid bilayer structure prevents encapsulated medications from degrading, facilitating more effective distribution to the intended location.

To target certain tissues or cells, liposomes can be functionalized with ligands (such as aptamers, peptides, or antibodies) or designed with specific surface characteristics. Because the medicine is concentrated in the desired region, like tumors or inflammatory tissues, this targeting capability lowers the chance of off-target effects and systemic toxicity.[11]

Doxil® (doxorubicin), a chemotherapy medication encapsulated in liposomes, is one of the most well-known and frequently used liposomal formulations. By boosting drug accumulation within tumors and lowering side effects including cardiotoxicity, which are frequent with conventional doxorubicin therapy, Doxil® has shown improved efficacy when compared to standard doxorubicin. Additionally, liposomal formulation reduces harm to healthy cells, which improves therapeutic results and lowers toxicity.[12]

Because of their versatility, liposomes can be utilized to administer a wide range of medications, including vaccinations, antibiotics, anti-inflammatory medicines, and chemotherapeutic agents. They are a promising platform in nanomedicine for treating a variety of diseases, especially cancer and inflammatory conditions, because of their capacity to improve the therapeutic index of medications by enhancing solubility and targeting, as well as their biocompatibility and biodegradability.[13]

**Polymeric Nanoparticles**

Polymeric nanoparticles are a promising drug delivery system, often created using biodegradable polymers like polylactic acid (PLA) and poly (lactic-co-glycolic acid) (PLGA). These polymers are widely used due to their biocompatibility and biodegradability, which allows them to break down safely in the body over time, minimizing long-term toxicity. PLGA is one of the most used materials for creating nanoparticles due to its ability to provide sustained and controlled drug release. When drugs are encapsulated in PLGA nanoparticles, the drug is gradually released as the polymer degrades, allowing for prolonged therapeutic effects with fewer doses. This controlled release minimizes the fluctuations in drug concentrations that can occur with

conventional drug delivery methods, reducing side effects and improving overall treatment outcomes.[14]

Polymeric nanoparticles can encapsulate a wide variety of therapeutic agents, including small molecules, proteins, peptides, and even nucleic acids. The polymeric matrix protects the drug from degradation, enhances its stability, and can be engineered to release the drug at a desired rate depending on the polymer composition, the type of drug, and the desired therapeutic outcome. Moreover, the surface of polymeric nanoparticles can be modified with functional groups or ligands (e.g., antibodies or peptides) to target specific cells or tissues, offering an extra layer of precision in drug delivery. This targeting capability is particularly useful in cancer therapy, where polymeric nanoparticles can deliver chemotherapeutic agents directly to tumor cells, minimizing exposure to healthy tissues and reducing systemic toxicity.[15]

Overall, polymeric nanoparticles are a versatile and effective platform for drug delivery, with significant applications in cancer therapy, gene delivery, vaccines, and chronic disease management, offering the advantage of enhanced drug bioavailability, reduced dosing frequency, and improved patient adherence.[16]

**Dendrimers**

Because of their distinct, nanoscale structure, dendrimers—highly branched, tree-like polymers—offer special benefits in drug delivery. Drugs, proteins, nucleic acids, and other medicinal substances can be efficiently encapsulated or attached to dendrimers thanks to their distinctive branching, which provides exact control over the quantity and configuration of functional groups on their surface. Because of their structure, dendrimers are perfect for regulated and targeted medication delivery.[17]

**Important Dendrimer Features:**

**Precise Drug Loading:**

A great degree of control over drug loading is possible by engineering dendrimers to carry a predetermined number of drug molecules. This accuracy is especially crucial when administering medications that are extremely sensitive or powerful.[18]

**Multifunctionality:**

Different functional groups or ligands can be added to the surface of dendrimers to modify them for interactions with target tissues or cells. Because of this characteristic, dendrimers are especially helpful for targeted drug delivery, such as delivering gene therapy medicines to organs or anticancer medications to tumor cells.[19]

**Regulated Release:**

Systems that release medications in a regulated way can be designed thanks to the architecture of dendrimers. The medications can be released by enzymatic activity, pH changes, or dendrimer structural disintegration, providing prolonged release profiles that can enhance therapeutic impact and lessen adverse effects.[20]

**Targeted Delivery:**

Dendrimers can bind selectively to receptors on immune cells, cancer cells, or other target tissues by functionalizing their surface with targeting molecules like peptides, antibodies, or small molecules. This feature is very helpful in anticancer treatments since dendrimers can carry medications to tumor cells only, causing the least amount of damage to nearby healthy tissues.[21]

**Drug Delivery Applications:**

**Gene therapy**

The potential of dendrimers to transport genetic material, like DNA or RNA, to cells is being investigated. Because of their structure, nucleic acids can be attached or encapsulated, improving cellular absorption and offering a stable, secure environment for gene delivery.[22]

**Cancer Therapy**

The delivery of anticancer drugs by dendrimers shows great promise. Dendrimers can be engineered to deliver chemotherapeutic drugs directly to tumors, increasing efficacy while lowering systemic toxicity because of their size and surface modification capabilities. An additional benefit in the treatment of cancer is their capacity to transport several medications or combine therapy and imaging agents (theranostics).[23]

**Drug Combination Therapies**

Using dendrimers to combine several therapeutic drugs in one delivery system is also beneficial. This may enable synergistic effects, in which various medications cooperate to improve therapeutic results, as in the case of combination cancer treatments or the management of infections that are resistant to multiple agents.[24]

**Inorganic Nanoparticles**

Because of their special qualities and adaptability, inorganic nanoparticles—like silica and gold nanoparticles—are receiving a lot of attention in the field of drug delivery. In addition to being effective drug delivery vehicles, these nanoparticles facilitate simultaneous diagnostic imaging—a process called theranostics that integrates treatment and diagnostics on a single platform.[25]

**AuNPs, or gold nanoparticles:**

Gold nanoparticles' unique visual, chemical, and biocompatible qualities have made them popular in nanomedicine. Targeted medication delivery to cells or tissues is made possible by their ease of functionalization with a variety of ligands, including peptides and antibodies. Additionally, gold nanoparticles have special optical qualities including surface plasmon resonance (SPR), which can be used for diagnostics and imaging.[26]

**Theranostics applications:**

**Drug Delivery**

Drugs can be conjugated with gold nanoparticles or encapsulated in them. By altering their surface for controlled release, medications can be sent straight to target tissues or cells, including tumor cells, enhancing therapeutic results and reducing adverse effects.[27]

**Imaging:**

Gold nanoparticles work very well in imaging methods such as computed tomography (CT) imaging and photoacoustic imaging. Gold nanoparticles' high atomic number makes them useful for real-time tracking of drug distribution and targeting because it increases contrast in CT scans. Drug administration and imaging are two applications for gold nanoparticles in cancer therapy. Furthermore, when exposed to near-infrared light, gold nanoparticles can undergo localized heating, a treatment method known as photothermal therapy, in which the heat produced by the particle's aids in the destruction of cancer cells.[28]

**Nanoparticles of silica (SiNPs)**

Because of their porous nature, biocompatibility, and simplicity of surface modification, silica nanoparticles are frequently employed in drug administration and imaging. These nanoparticles can be designed to release their payload in response to environmental stimuli like pH or temperature, and they are frequently employed to load and transport a variety of medications, from tiny compounds to bigger biologics.[29]

**Theranostics applications**

**Drug Delivery**

Silica nanoparticles are adaptable carriers for a range of treatments because they may be made to carry both hydrophilic and hydrophobic medications. High drug-loading capacity is made possible by their porous nature, and prolonged drug delivery can be achieved by integrating controlled release mechanisms.

Imaging: Magnetic resonance imaging (MRI) and fluorescence imaging are two imaging techniques that can make use of silica nanoparticles. To visualize drug distribution and treatment effects in real time, their surface can be functionalized with substances that improve contrast in various imaging methods.[30]

**Imaging and Cancer:**

Silica nanoparticles have been designed to both transport anticancer medications and act as contrast agents for fluorescence or magnetic resonance imaging. This dual feature reduces the need for intrusive diagnostic procedures and improves the precision of cancer therapy by enabling simultaneous treatment and monitoring.[31]

**Theranostics**

**Integrating Diagnostics and Therapy**

One important development in customized medicine is the integration of drug delivery and diagnostic capabilities onto a single platform. The following is made possible by theranostic nanoparticles.[32]

**Targeted Treatment:**

By delivering medications straight to the locations of disease, therapeutic efficacy can be increased. With the use of imaging capabilities, doctors can keep tabs on medication distribution and treatment response, enabling real-time modifications.[33]

**Decreased Side Effects:**

Theranostic nanoparticles minimize systemic exposure to medications and eliminate the need for several diagnostic procedures, which reduces side effects.

**Challenges and Limitations**

Even while drug delivery has advanced significantly thanks to nanotechnology, there are still several obstacles and restrictions that could prevent the successful adoption of systems based on nanoparticles in clinical settings. These difficulties include, among other things, problems with safety, stability, scalability, regulatory approval, and biocompatibility.[34]

**Toxicity and Biocompatibility**

The biocompatibility of nanoparticles is one of the main issues in nanomedicine. As foreign substances, nanoparticles may trigger immunological reactions that result in toxicity, inflammation, or even allergic reactions. Furthermore, if nanoparticles are not appropriately made or eliminated from the body, their capacity to build up in different organs (such as the liver, spleen, or kidneys) may result in long-term toxicity. Biocompatible polymers or ligands can be added to the surface of nanoparticles to improve their removal from the body and lessen immune detection. Research on the long-term impacts is still ongoing, though.[35]

**Biodistribution and Pharmacokinetics**

Although nanoparticles can target organs, their pharmacokinetics are frequently unpredictable. The size, shape, surface charge, and biological milieu of nanoparticles all affect how they are distributed throughout the body. These variables may have an impact on the absorption, distribution, and excretion of nanoparticles from the body, which may lead to inefficient targeting or buildup in tissues that are not intended. Targeting accuracy can be increased

by using sophisticated targeting techniques, such as functionalizing nanoparticles with ligands that attach to receptors. Additionally, the pharmacokinetics and biodistribution profiles can be improved by adjusting the size and surface properties of nanoparticles.[36]

**Production and Expandability**

There are many obstacles to overcome when producing nanoparticles on a commercial scale from the lab. Throughout the manufacturing process, consistency in size, surface characteristics, and drug-loading capability must be preserved. Particularly for therapeutic applications, large-scale nanoparticle synthesis frequently necessitates exact control over the production process, which can be expensive and complicated. Creating standardized procedures for the synthesis of nanoparticles and implementing automated production techniques could aid in overcoming these difficulties. But producing on a commercially feasible scale continues to be a challenge.[37]

**Storage and Stability**

Aggregation can have an impact on the size, surface characteristics, and efficacy of drug delivery of nanoparticles. Over time, this aggregation may happen, especially when the nanoparticles are being stored or exposed to environmental conditions like pH or temperature changes. To preserve their structure and medication release profile, nanoparticles can be integrated into solid matrices (such hydrogels or liposomes) or prepared with stabilizing agents. Long-term stability is still difficult to achieve, though, particularly for biologically generated nanoparticles like dendrimers or liposomes.[38]

**Difficulties with Regulation**

Nanomedicine approval is still being developed. There are still questions about the precise regulatory criteria for nanoparticles, even though regulatory agencies like the FDA and the European Medicines Agency (EMA) have been creating frameworks to evaluate the safety and effectiveness of therapeutics based on nanotechnology. The creation of novel medications based on nanoparticles may be slowed delayed by the absence of established standards. More precise testing procedures and regulatory criteria will be created as nanomedicine research advances. To speed up the approval process, this entails setting safety limits, toxicity testing procedures, and clinical trial protocols.[39]

**Expense and Marketing**

Drug delivery systems based on nanotechnology are costly to build because they frequently need significant research and development expenditures. The high expense of these treatments is also a result of their complicated production and requirement for specific tools and procedures. The cost-effectiveness of treatments based on nanoparticles must be increased for these technologies to become economically feasible. Production costs may be lowered by developments in manufacturing technologies like high-throughput screening and nanofabrication. Furthermore, improving medicine delivery systems' efficiency may result in better outcomes at cheaper prices, making them more accessible for mass use.[40]

**Selectivity and Targeting Efficiency**

Targeting efficiency is still a problem even if systems based on nanoparticles can be made to target cells or regions. Off-target effects and non-specific binding might raise the likelihood of adverse effects and decrease therapeutic efficacy. Optimization is still needed to achieve high specificity and selectivity, particularly in complex tissues like brains or malignancies. Increasing selectivity may be possible with the creation of multifunctional nanoparticles that incorporate therapeutic payloads, imaging agents, and targeting ligands. To improve targeting accuracy,

nanoparticles can also be engineered to react to environmental cues (such pH or temperature) that are typical of sick tissues.[41]

**Environmental Impact and Long-Term Safety**

There is still much to learn about the long-term safety of nanoparticles in the environment and in medicinal applications. Even though most nanoparticles are made to biodegrade, further research is necessary to fully understand the breakdown products and their possible impacts on the environment and human health. To overcome this issue, biodegradable and biocompatible materials such as dendrimers, liposomes, and PLGA are frequently utilized. Research on the effects of nanoparticle use on the environment is still ongoing, and creating more environmentally friendly substitutes will be essential to guaranteeing their sustainability.[42]

**Future Perspectives**

Enhancing the specificity and effectiveness of medicine delivery systems is probably the main goal of nanotechnology advancements. Novel approaches such as CRISPR-based nanosystems and bio-inspired nanoparticles (such exosomes) have the potential to treat genetic illnesses. Combining machine learning and artificial intelligence could improve nanoparticle design and forecast therapeutic results.[43]

**Conclusion**

To sum up, medication delivery using nanotechnology has the potential to completely transform how we treat illnesses by providing previously unheard-of possibilities for targeted therapy, improved drug solubility, controlled release, and breaking down cellular barriers. The creation of liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles like silica and gold has led to new developments in drug delivery systems and may provide answers for gene therapy, customized medicine, and cancer treatment. By incorporating these platforms into theranostic systems, therapy and diagnostic imaging can be administered concurrently, increasing treatment accuracy and effectiveness.

Notwithstanding these developments, several problems still exist, such as those pertaining to nanoparticles' long-term stability, toxicity, scalability, regulatory approval, and biocompatibility. The successful integration of medication delivery systems based on nanotechnology into clinical practice will depend on overcoming these obstacles. To address environmental issues, the area will also place more and more focus on developing eco-friendly and biodegradable materials as well as intelligent, responsive nanoparticles.

With ongoing research likely to produce new, more potent treatments, particularly in complicated conditions like cancer and neurological disorders, the future of nanotechnology in drug delivery is bright. Real-time imaging combined with the development of genes, combination, and personalized medicines will greatly increase treatment accuracy, decrease side effects, and improve patient outcomes. The next generation of tailored medicines and precision medicine will be fueled by nanomedicine, which is poised to become a fundamental component of contemporary healthcare as these technologies advance.

**References**

[1] Joseph TM, Kar Mahapatra D, Esmaeili A, Piszczyk Ł, Hasanin MS, Kattali M, Haponiuk J, Thomas S. Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials (Basel). 2023 Jan 31;13(3):574. doi: 10.3390/nano13030574. PMID: 36770535; PMCID: PMC9920911.

[2] Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022 May 13;8(5):e09394. doi: 10.1016/j.heliyon.2022.e09394. PMID: 35600452; PMCID: PMC9118483.

[3] Sun R, Chen Y, Pei Y, Wang W, Zhu Z, Zheng Z, Yang L, Sun L. The drug release of PLGA-based nanoparticles and their application in treatment of gastrointestinal cancers. Heliyon. 2024 Sep 19;10(18):e38165. doi: 10.1016/j.heliyon.2024.e38165. PMID: 39364250; PMCID: PMC11447355.

[4] Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules. 2020 May 8;25(9):2193. doi: 10.3390/molecules25092193. PMID: 32397080; PMCID: PMC7248934.

[5] Markovic M, Zur M, Ragatsky I, Cvijić S, Dahan A. BCS Class IV Oral Drugs and Absorption Windows: Regional-Dependent Intestinal Permeability of Furosemide. Pharmaceutics. 2020 Dec 2;12(12):1175. doi: 10.3390/pharmaceutics12121175. PMID: 33276565; PMCID: PMC7761534.

[6] Leila Farhoudi, Seyedeh Maryam Hosseinikhah, Fatemeh Vahdat-Lasemi, Vasily N. Sukhorukov, Prashant Kesharwani, Amirhossein Sahebkar, Polymeric micelles paving the Way: Recent breakthroughs in camptothecin delivery for enhanced chemotherapy, International Journal of Pharmaceutics, Volume 659, 2024, 124292, ISSN 0378-5173, https://doi.org/10.1016/j.ijpharm.2024.124292.

[7] Dilpreet Singh, Vrinda Krishna, Nitya Kumari, Anoushka Banerjee, Prithviraj Kapoor, Nano-engineered solutions for extensively drug-resistant tuberculosis (XDR-TB): A novel nanomedicine, Nano-Structures & Nano-Objects, Volume 40, 2024, 101390, ISSN 2352-507X, https://doi.org/10.1016/j.nanoso.2024.101390.

[8] Niazi SK. Non-Invasive Drug Delivery across the Blood-Brain Barrier: A Prospective Analysis. Pharmaceutics. 2023 Nov 7;15(11):2599. doi: 10.3390/pharmaceutics15112599. PMID: 38004577; PMCID: PMC10674293.

[9] Ding S, Khan AI, Cai X, Song Y, Lyu Z, Du D, Dutta P, Lin Y. Overcoming blood-brain barrier transport: Advances in nanoparticle-based drug delivery strategies. Mater Today (Kidlington). 2020 Jul-Aug;37:112-125. doi: 10.1016/j.mattod.2020.02.001. Epub 2020 Mar 4. PMID: 33093794; PMCID: PMC7575138.

[10] Mittal KR, Pharasi N, Sarna B, Singh M, Rachana, Haider S, Singh SK, Dua K, Jha SK, Dey A, Ojha S, Mani S, Jha NK. Nanotechnology-based drug delivery for the treatment of CNS

disorders. Transl Neurosci. 2022 Dec 31;13(1):527-546. doi: 10.1515/tnsci-2022-0258. PMID: 36741545; PMCID: PMC9883694.

[11] Sivadasan D, Sultan MH, Alqahtani SS, Javed S. Cubosomes in Drug Delivery-A Comprehensive Review on Its Structural Components, Preparation Techniques and Therapeutic Applications. Biomedicines. 2023 Apr 7;11(4):1114. doi: 10.3390/biomedicines11041114. PMID: 37189732; PMCID: PMC10135881.

[12] Lee J, Choi MK, Song IS. Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting. Pharmaceuticals (Basel). 2023 May 29;16(6):802. doi: 10.3390/ph16060802. PMID: 37375753; PMCID: PMC10301446.

[13] Dejeu, I.L.; Vicaș, L.G.; Marian, E.; Ganea, M.; Frenț, O.D.; Maghiar, P.B.; Bodea, F.I.; Dejeu, G.E. Innovative Approaches to Enhancing the Biomedical Properties of Liposomes. Pharmaceutics 2024, 16, 1525. https://doi.org/10.3390/pharmaceutics16121525

[14] Shama Parveen, Pratishtha Gupta, Saurabh Kumar, Monisha Banerjee, Lipid polymer hybrid nanoparticles as potent vehicles for drug delivery in cancer therapeutics, Medicine in Drug Discovery, Volume 20, 2023, 100165, ISSN 2590-0986, https://doi.org/10.1016/j.medidd.2023.100165.

[15] Sánchez A, Mejía SP, Orozco J. Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections. Molecules. 2020 Aug 18;25(16):3760. doi: 10.3390/molecules25163760. PMID: 32824757; PMCID: PMC7464666.

[16] Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, Thamaraikani T, Vasanthan M, Viktor P, Lakshmaiya N, Saadh MJ, Amajd A, Abo-Zaid MA, Castillo-Acobo RY, Ismail AH, Amin AH, Akhavan-Sigari R. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023 Oct 9;22(1):169. doi: 10.1186/s12943-023-01865-0. PMID: 37814270; PMCID: PMC10561438.

[17] Mittal P, Saharan A, Verma R, Altalbawy FMA, Alfaidi MA, Batiha GE, Akter W, Gautam RK, Uddin MS, Rahman MS. Dendrimers: A New Race of Pharmaceutical Nanocarriers. Biomed Res Int. 2021 Feb 15;2021:8844030. doi: 10.1155/2021/8844030. PMID: 33644232; PMCID: PMC7902124.

[18] Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules. 2021 Sep 29;26(19):5905. doi: 10.3390/molecules26195905. PMID: 34641447; PMCID: PMC8512302.

[19] Sun, L., Liu, H., Ye, Y. et al. Smart nanoparticles for cancer therapy. Sig Transduct Target Ther 8, 418 (2023). https://doi.org/10.1038/s41392-023-01642-x

[20] Mikušová V, Mikuš P. Advances in Chitosan-Based Nanoparticles for Drug Delivery. Int J Mol Sci. 2021 Sep 6;22(17):9652. doi: 10.3390/ijms22179652. PMID: 34502560; PMCID: PMC8431817.

[21] Crintea A, Motofelea AC, Șovrea AS, Constantin AM, Crivii CB, Carpa R, Duțu AG. Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment-An Overview. Pharmaceutics. 2023 May 4;15(5):1406. doi: 10.3390/pharmaceutics15051406. PMID: 37242648; PMCID: PMC10221618.

[22] Zhu Y, Liu C, Pang Z. Dendrimer-Based Drug Delivery Systems for Brain Targeting. Biomolecules. 2019 Nov 27;9(12):790. doi: 10.3390/biom9120790. PMID: 31783573; PMCID: PMC6995517.

[23] Jarmila Prieložná, Veronika Mikušová, Peter Mikuš, Advances in the delivery of anticancer drugs by nanoparticles and chitosan-based nanoparticles, International Journal of Pharmaceutics: X, Volume 8, 2024, 100281, ISSN 2590-1567, https://doi.org/10.1016/j.ijpx.2024.100281.

[24] Abedi-Gaballu F, Dehghan G, Ghaffari M, Yekta R, Abbaspour-Ravasjani S, Baradaran B, Dolatabadi JEN, Hamblin MR. PAMAM dendrimers as efficient drug and gene delivery nanosystems for cancer therapy. Appl Mater Today. 2018 Sep;12:177-190. doi: 10.1016/j.apmt.2018.05.002. Epub 2018 May 29. PMID: 30511014; PMCID: PMC6269116.

[25] Huang H, Liu R, Yang J, Dai J, Fan S, Pi J, Wei Y, Guo X. Gold Nanoparticles: Construction for Drug Delivery and Application in Cancer Immunotherapy. Pharmaceutics. 2023 Jul 2;15(7):1868. doi: 10.3390/pharmaceutics15071868. PMID: 37514054; PMCID: PMC10383270.

[26] Alshayma N. Al-Thani, Asma Ghafoor Jan, Mohamed Abbas, Mithra Geetha, Kishor Kumar Sadasivuni, Nanoparticles in cancer theragnostic and drug delivery: A comprehensive review, Life Sciences, Volume 352, 2024, 122899, ISSN 0024-3205, https://doi.org/10.1016/j.lfs.2024.122899.

[27] Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front Mol

Biosci. 2020 Aug 20;7:193. doi: 10.3389/fmolb.2020.00193. PMID: 32974385; PMCID: PMC7468194.

[28] Mahan, Matthew M., Doiron, Amber L., Gold Nanoparticles as X-Ray, CT, and Multimodal Imaging Contrast Agents: Formulation, Targeting, and Methodology, Journal of Nanomaterials, 2018, 5837276, 15 pages, 2018. https://doi.org/10.1155/2018/5837276

[29] Dutta Gupta, Y., Mackeyev, Y., Krishnan, S. et al. Mesoporous silica nanotechnology: promising advances in augmenting cancer theranostics. Cancer Nano 15, 9 (2024). https://doi.org/10.1186/s12645-024-00250-w

[30] Rozhan Khoz, Fateme Yazdian, Mehrab Pourmadadi, Abbas Rahdar, Sonia Fathi-karkan, Sadanand Pandey, Current trends in silica based drug delivery systems, European Journal of Medicinal Chemistry Reports, Volume 12, 2024, 100206, ISSN 2772-4174, https://doi.org/10.1016/j.ejmcr.2024.100206.

[31] Wang, B., Hu, S., Teng, Y. et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Sig Transduct Target Ther 9, 200 (2024). https://doi.org/10.1038/s41392-024-01889-y

[32] Matteo Puccetti, Marilena Pariano, Aurélie Schoubben, Stefano Giovagnoli, Maurizio Ricci, Biologics, theranostics, and personalized medicine in drug delivery systems, Pharmacological Research, Volume 201, 2024, 107086, ISSN 1043-6618, https://doi.org/10.1016/j.phrs.2024.107086.

[33] Mason M, Cho Y, Rayo J, Gong Y, Harris M, Jiang Y. Technologies for Medication Adherence Monitoring and Technology Assessment Criteria: Narrative Review. JMIR Mhealth Uhealth. 2022 Mar 10;10(3):e35157. doi: 10.2196/35157. PMID: 35266873; PMCID: PMC8949687.

[34] Nasim Ebrahimi, Mahdokht Sadat Manavi, Ahmad Nazari, Amirali Momayezi, Ferdos Faghihkhorasani, Al-Hasnawi Rasool Riyadh Abdulwahid, Fatemeh Rezaei-Tazangi, Mohammed Kavei, Roya Rezaei, Halimeh Mobarak, Amir Reza Aref, Wei Fang, Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology, Environmental Research, Volume 239, Part 2, 2023, 117263, ISSN 0013-9351, https://doi.org/10.1016/j.envres.2023.117263.

[35] Kyriakides TR, Raj A, Tseng TH, Xiao H, Nguyen R, Mohammed FS, Halder S, Xu M, Wu MJ, Bao S, Sheu WC. Biocompatibility of nanomaterials and their immunological properties.

Biomed Mater. 2021 Mar 11;16(4):10.1088/1748-605X/abe5fa. doi: 10.1088/1748-605X/abe5fa. PMID: 33578402; PMCID: PMC8357854.

[36] Haripriyaa, M., Suthindhiran, K. Pharmacokinetics of nanoparticles: current knowledge, future directions and its implications in drug delivery. Futur J Pharm Sci 9, 113 (2023). https://doi.org/10.1186/s43094-023-00569-y

[37] Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012 Jun;14(2):282-95. doi: 10.1208/s12248-012-9339-4. Epub 2012 Mar 10. PMID: 22407288; PMCID: PMC3326161.

[38] Mitchell, M.J., Billingsley, M.M., Haley, R.M. et al. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20, 101–124 (2021). https://doi.org/10.1038/s41573-020-0090-8

[39] Đorđević S, Gonzalez MM, Conejos-Sánchez I, Carreira B, Pozzi S, Acúrcio RC, Satchi-Fainaro R, Florindo HF, Vicent MJ. Current hurdles to the translation of nanomedicines from bench to the clinic. Drug Deliv Transl Res. 2022 Mar;12(3):500-525. doi: 10.1007/s13346-021-01024-2. Epub 2021 Jul 23. PMID: 34302274; PMCID: PMC8300981.

[40] Milewska S, Niemirowicz-Laskowska K, Siemiaszko G, Nowicki P, Wilczewska AZ, Car H. Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment. Int J Nanomedicine. 2021 Sep 28;16:6593-6644. doi: 10.2147/IJN.S323831. PMID: 34611400; PMCID: PMC8487283.

[41] Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG, Ogbodo JO, Umeh BU, Ossai EC, Nwanguma BC. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 24;9(6):e17488. doi: 10.1016/j.heliyon.2023.e17488. PMID: 37416680; PMCID: PMC10320272.

[42] Remya, R. R., Julius, Angeline, Suman, T. Y., Mohanavel, V., Karthick, Alagar, Pazhanimuthu, C., Samrot, Antony V., Muhibbullah, M., Role of Nanoparticles in Biodegradation and Their Importance in Environmental and Biomedical Applications, Journal of Nanomaterials, 2022, 6090846, 15 pages, 2022. https://doi.org/10.1155/2022/6090846

[43] Remya, R. R., Julius, Angeline, Suman, T. Y., Mohanavel, V., Karthick, Alagar, Pazhanimuthu, C., Samrot, Antony V., Muhibbullah, M., Role of Nanoparticles in Biodegradation and Their Importance in Environmental and Biomedical Applications, Journal of Nanomaterials, 2022, 6090846, 15 pages, 2022. https://doi.org/10.1155/2022/6090846